Intellikine

Takeda to acquire Intellikine for $190 million

Wednesday, December 21, 2011

Takeda Pharmaceutical and Intellikine have entered into an agreement for Takeda America Holdings to acquire Intellikine by cash. Takeda expects that the transaction will be finalized in January 2012. Under the agreement, Takeda America Holdings will acquire Intellikine for $190 million upfront and up to $120 million in additional potential clinical development milestone payments.

[Read More]